4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
Author:
Affiliation:
1. From the Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; and Department of Surgery, Emory University School of Medicine, Atlanta, Georgia 30322
Abstract
Publisher
Rockefeller University Press
Subject
Immunology,Immunology and Allergy
Link
http://rupress.org/jem/article-pdf/186/1/47/1112131/97-0194.pdf
Reference12 articles.
1. Novel T cell antigen 4-1BB associates with the protein tyrosine kinase p56lck1;Kim;J Immunol,1993
2. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death;Smith;Cell,1994
3. Inducible T cell antigen 4-1BB. Analysis of expression and function;Pollok;J Immunol,1993
4. Regulation of immune responses by the ligands for CD27, CD30, and 4-1BB;Alderson;Circulatory Shock,1995
5. Molecular and biological characterization of human 4-1BB and its ligand;Alderson;Eur J Immunol,1994
Cited by 682 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer;International Immunopharmacology;2024-08
2. Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells;Journal for ImmunoTherapy of Cancer;2024-07
3. Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells;2024-05-14
4. Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy;Cell Reports;2024-05
5. CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors;Clinical Cancer Research;2024-04-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3